Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q2 2023 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2022 Net Income-$9.91M-$9.91MN/M vs Q2 2022 EPS, diluted—
Operating Income-$10,227,000N/M Operating Cash Flowderived-$9,202,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$9,218,000N/M ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end